Reuters logo
BRIEF-Redhill Biopharma received notices of allowance from USPTO for 2 new patents covering Bekinda
April 18, 2017 / 12:19 PM / 5 months ago

BRIEF-Redhill Biopharma received notices of allowance from USPTO for 2 new patents covering Bekinda

April 18 (Reuters) - Redhill Biopharma Ltd

* Redhill biopharma - received notices of allowance from USPTO for 2 new patents covering Bekinda, expected to be valid until at least 2034, once granted

* Redhill Biopharma Ltd - top-line results from a phase III study with Bekinda 24 mg for acute gastroenteritis and gastritis expected in Q2 2017

* Redhill Biopharma - phase II study with Bekinda 12 mg for diarrhea-predominant irritable bowel syndrome is ongoing, top-line results expected in Q3 2017 Source text for Eikon: (bit.ly/2puYz1l) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below